ClinicalTrials.Veeva

Menu
R

Retina Consultants San Diego | Poway, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

APL-2
Pegcetacoplan
ABP 938
GT005
Aflibercept
Triamcinolone Acetonide
JNJ-81201887
THR-149
Denufosol
Eylea®

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 20 total trials

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.

Enrolling
Geographic Atrophy
Drug: Triamcinolone
Other: Sham Procedure

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

The purpose of this Phase 1 study is comprised of multiple ascending-dose component (Part 1) and high concentration component (Part 2) to evaluate th...

Enrolling
Neovascular Age-related Macular Degeneration
Biological: AM712(ASKG712)

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) i...

Active, not recruiting
Neovascular Age-Related Macular Degeneration
Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Phase 2b, randomized, double-masked, parallel-group, active-controlled, multicenter, 36-week study designed to assess the safety and efficacy of supr...

Active, not recruiting
Neovascular Age-related Macular Degeneration
Drug: Aflibercept
Drug: CLS-AX

Trial sponsors

A
AbbVie logo
C
A
Amgen logo
Bayer logo
G
Ionis Pharmaceuticals logo
Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems